Allergic rhinitis (AR) is a common condition, affecting around 18% of people (children and adults) in Australia and New Zealand. AR has significant impact on quality-of-life, emotional wellbeing and productivity, especially for people with co-existing asthma. This education program is based on current AR management guidelines and is in line with models of integrated care.
This course reflects best practice from the Australasian Society of Clinical Immunology and Allergy (ASCIA) and guides pharmacists on how to assess AR and discuss pharmacological and non-pharmacological approaches to the management of moderate-to-severe disease with patients.
Using a person-centred approach to the management of AR, the program will detail the current AR treatment algorithm, including when to consider intra-nasal combination pharmacotherapy and when to refer.
This program is supported by an independent, educational grant provided from Viatris.